HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.

February 01, 2013 By:
  • Theys K
  • Vercauteren J
  • Snoeck J
  • Zazzi M
  • Camacho RJ
  • Torti C
  • Schulter E
  • Clotet B
  • Sonnerborg A
  • De Luca A
  • Grossman Z
  • Struck D
  • Vandamme AM
  • Abecasis AB.

Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.

2013 Feb. Antimicrob Agents Chemother.57(2):1053-6. Epub 2012 Nov 26.
Other information